Skip to content

Key Words: acitretin, adalimumab, alefacept, biologics, calcipotriol, combination therapy, cyclosporine, etanercept, infliximab, methotrexate, phototherapy, psoriasis

Key Words: acitretin, adalimumab, alefacept, biologics, calcipotriol, combination therapy, cyclosporine, etanercept, infliximab, methotrexate, phototherapy, psoriasis. Keywords: psoriasis, management, biological therapy, treatment. Cyclosporine is a widely used alternative to methotrexate, providing rapid and reliable improvement in psoriasis for up to 80 90 of patients. 48 A consensus conference in 2004 determined that combination therapy with acitretin and phototherapy is an underutilized therapeutic option that is both safe and effective. Keywords: Acitretin, Biologics, Erythrodermic psoriasis, Palmoplantar psoriasis, Psoriasis, Pustular psoriasis, Methotrexate, TNF- inhibitor. Combinations of phototherapy with other agents have been reported, allowing it to be an adjuvant to any of the prior failed monotherapy options. UV light has been combined with a few biologics, notably etanercept and alefacept.

Key Words: acitretin, adalimumab, alefacept, biologics, calcipotriol, combination therapy, cyclosporine, etanercept, infliximab, methotrexate, phototherapy, psoriasis 2Keywords: Acitretin, Biologics, Methotrexate, Psoriasis, Psoriatic nail disease, Severe scalp psoriasis, TNF- inhibitor. Potential psoriasis treatment options generated during the Delphi process. Currently, the biologic agents approved by the US FDA for the treatment of psoriasis include alefacept, efalizumab, etanercept, infliximab and adalimumab, while ustekinumab has been recommended for approval. A combination of systemic cyclosporine with topical calcipotriol twice a day for 3 months showed a better overall result in both mild and severe nail psoriasis. Key words: Isotretinoin; Methotrexate; Psoriasis; Retinoids. UVB phototherapy) or systemic therapies (methotrexate, retinoids, cyclosporine A, PUVA (psoralens+UVA), hydroxyurea, biologics), used alone or in combination with topical therapies, control the severity and extent of psoriasis. The biologics (alefacept, infliximab, adalimumab, etanercept, efalizumab) offer better safety profile but cost and availability remain prohibitory.

Novel psoriasis therapies and patient outcomes, part 2: biologic treatments. Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. Acitretin in dermatology: a review.

A Delphi Consensus Approach To Challenging Case Scenarios In Moderate-to-severe Psoriasis: Part 1

Key Words: acitretin, adalimumab, alefacept, biologics, calcipotriol, combination therapy, cyclosporine, etanercept, infliximab, methotrexate, phototherapy, psoriasis 3

Unbound Medline